|Day Low/High||93.47 / 95.80|
|52 Wk Low/High||58.59 / 98.97|
It's likely that investors will be closely watching the U.S.-China trade talks to see if the skies brighten longer term.
Pharma companies that have cash are looking at what has happened to this stock market and buying.
And it is happening not a moment too soon.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.
The big problem this market faces technically is that there isn't much support down to the lows hit on Dec. 24.
The market's day-to-day extreme volatility tested even the most seasoned investors. Adhering to portfolio principles can help.
It can be disturbing to see various names lose value quickly on no news, but here is a method to take advantage of such moves.
Both names looked poised to go higher as soon as sentiment around the small biotech sector improves.
Celgene could be at a temporary low or it could be starting a new base pattern.
I tire of hearing that there has been a correction.
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
I continue to deploy 'dry powder' into the biotech sector on dips using Buy-Write option strategies.
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
It becomes difficult for me to tell you where to run in these markets...
Upcoming results from these names -- and many others -- should reassure investors.
This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
Investors might be finally recognizing the hidden value of the firms' drug research and development.
With biotech names getting some attention this morning a quick review looks like a good idea.
Taking the measure of what's keeping the markets in the dumps.
After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene or Gilead.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks from the floor of the New York Stock Exchange.
The April Jobs report showed that 164,000 jobs were created last month. This is nearly 30,000 jobs less than the consensus. Unemployment rates tumbles to 3.9%, the first time under the 4% level in almost two decades. A rash of biotech news hitting t...